🎉Congratulations 🎉to Dr. Sohyun An (@DrAn2021) on their Innovations in Research on Equity and Social Justice in Teaching and Teacher Education Award. Thank you to the chair @AubryThrelkeld and members @deckman_sherry and Elizabeth Blair.
Finally!
Check out this paper from my time with @kwonjean@sjknechtle at @DukeU - persistent GC suppression with Belatacept maintenance in pregnancy sensitised recipients.
🙏Dr Knechtle & Jean Kwun for supporting gender parity in research.
https://t.co/Oo6FfCFVL0
Pre-existing donor-specific antibody to major histocompatibility complex antigens reduces graft survival. This study shows a belatacept-based maintenance immunosuppression, in combination with desensitization, enables long-term graft survival https://t.co/e62g0H4Vkb
@kwonjean rounding up so much learning from the Knechtle lab about how to desensitize & maintain the most highly sensitized transplant patients using a dual targeting approach @ATCMeeting #ATC2022Boston @isadelaura
Honored to be a part of such an amazing group! Great talks today from @kwonjean@miriammanook on xenotransplantation and transplantation in sensitized multiparous females 🐒🥼🧫
Congratulations to Dr. Sohyun An as our 2022 #BCOE Faculty Award Winner for Outstanding Scholarship of Teaching and Learning (SoTL)! 🏆 @DrAn2021@kennesawstate@BCOEEECE
I am thrilled to share that our work was published today in @NatureComms.
🔹C3 complement inhibition prevents AMR in sensitized nonhuman primates.
Thank you to the Knechtle lab and all collaborators for their hard work.
@DukeSurgery@DukeSurgRes
https://t.co/oShDQOjK3q
Read our latest research on targeting complement in sensitized NHPs, published with @SpringerNature in @NatureComms - C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized… https://t.co/UG6RQNMIE3